Patent · US Active

Targeting opposite strand replication intermediates of single-stranded viruses by RNAI

US9198927B2 · kind B2 · utility

0Cited by

4References

21Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Daniel E. McCallus · Cambridge, US
Catherine Pachuk · Cambridge, US
Baohua Gu · Oak Ridge, US

Key dates

Filing date	Mar 1, 2010
Grant date	Dec 1, 2015
Priority date	—
Expiry date	Mar 1, 2030

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to methods and compositions for modulating viral replication through double-stranded RNA-mediated gene silencing (RNAi), wherein the antiviral methods and compositions preferentially target opposite strand replication intermediates of single-stranded RNA viruses.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.